{"id":1010065,"date":"2026-10-14T08:22:19","date_gmt":"2026-10-14T12:22:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/"},"modified":"2026-10-14T08:22:19","modified_gmt":"2026-10-14T12:22:19","slug":"tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/","title":{"rendered":"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference"},"content":{"rendered":"
\n

HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (\u201cTvardi\u201d or the \u201cCompany\u201d) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan\u2019s 10th<\/sup> Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.<\/p>\n

Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference.<\/p>\n

\n About Tvardi Therapeutics<\/strong>\n <\/p>\n

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in gastrointestinal (GI) diseases pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b\/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708<\/u><\/a>). To learn more, please visit tvarditherapeutics.com<\/u><\/a> or follow us on LinkedIn<\/u><\/a>and X (Twitter)<\/u><\/a>.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n For Tvardi:<\/strong>
\n
Tvardi Investor Relations
ir@tvardi.com<\/a><\/p>\n

PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (\u201cTvardi\u201d or the \u201cCompany\u201d) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan\u2019s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET. Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across … <\/p>\n

Continue reading “Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1010065","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (\u201cTvardi\u201d or the \u201cCompany\u201d) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan\u2019s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET. Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across … Continue reading "Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-14T12:22:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference\",\"datePublished\":\"2026-10-14T12:22:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/\"},\"wordCount\":238,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/\",\"name\":\"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==\",\"datePublished\":\"2026-10-14T12:22:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference - Market Newsdesk","og_description":"HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (\u201cTvardi\u201d or the \u201cCompany\u201d) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan\u2019s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET. Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across … Continue reading \"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-14T12:22:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference","datePublished":"2026-10-14T12:22:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/"},"wordCount":238,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/","name":"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==","datePublished":"2026-10-14T12:22:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTE5NCM3ODk0Mjc2IzUwMDEzMjg0Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tvardi-therapeutics-to-participate-in-chardans-10th-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tvardi Therapeutics to Participate in Chardan\u2019s 10th Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1010065"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010065\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1010065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1010065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1010065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}